Compare Stocks

Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; and OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC. In addition, the company provides ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and brPROPHET, a pre-operative ctDNA detection and post-operative MRD calling for relapsed patients. Further, it has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, and IMPACT Therapeutics and Merck KGaA. Additionally, the company offers OncoMaster, an automatic NGS data analysis and report interpretation machine for in-hospital model. Burning Rock Biotech Limited was incorporated in 2014 and is headquartered in Guangzhou, China.

King's Bay Resources Corp. engages in acquiring, exploring, developing, and evaluating mineral resource properties in Canada. The company has 100% interests in the Lynx Lake cobalt-copper property consisting of 66 mineral claims covering 20 square kilometers located in southern Labrador; and the Trump Island property consisting of 8 mineral claims covering an area of 2 square kilometers located in north-central Newfoundland. It also has interests in the Ninuk Lake project consisting of 19 mineral claims comprising 2,164 acres located to the northeast of Umiujag, Quebec; the Broadback River project consisting of 9 mineral claims covering an area of 1035 acres located to the northwest of the Nuinsco Discovery zone, Quebec; and the Roberge project consisting of 3 mineral claims comprising 443 acres located to the southeast of Chesterville, Quebec. The company was formerly known as King's Bay Gold Corporation and changed its name to King's Bay Resources Corp. in August 2017. King's Bay Resources Corp. was incorporated in 1998 and is headquartered in Vancouver, Canada.

MedX Health Corp develops, manufactures, and markets skin related screening tools and phototherapy devices for pain relief and tissue repair in Canada, the United States, and internationally. The company offers SIAscopy, a medical device technology used to scan skin for suspicious moles and lesions; and phototherapeutic medical devices, which use light energy in lower-level laser and LED to provide treatment for pain and tissue damage in the rehabilitation market. It operates DermSecure telemedicine platform that enables the web-based operation of its SIAscopy scanning technology and allows the company to deploy its technology in networks of third-party locations from which patients' mole and lesion images along with other relevant patient information can be connected to specialist physicians for remote assessment. The company was incorporated in 1999 and is headquartered in Mississauga, Canada.